Evidence map›Paper›PMID 33805900›Full record

ArticleJournal of personalized medicine2021

Systems Approaches to Treatment Response to Imatinib in Severe Asthma: A Pilot Study.

Seung Han Baek, Dinah Foer, Katherine N Cahill, Elliot Israel, Enrico Maiorino, Annika Röhl, Joshua A Boyce, Scott T Weiss

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Emerging Systemic Treatments for Asthma and Allergic Diseases: New Tricks, Same Dog?The journal of allergy and clinical immunology. In practice · 2026
    Review
  2. Targeting mitochondrial function as a potential therapeutic approach for allergic asthma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  3. Article
  4. Future directions in asthma pharmacogenomics.Annals of translational medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Seung Han BaekChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Dinah FoerDivision of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0717-5714
Katherine N CahillDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Elliot IsraelDivision of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Enrico MaiorinoChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0159-4221
Annika RöhlChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Joshua A BoyceDivision of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Scott T WeissChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-7196-303X
Brigham and Women's Hospital · USVanderbilt University Medical Center · US

Funding

Kit Inhibition in Asthma (KIA)U01HL102225 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BOYCE, JOSHUA A, ISRAEL, ELLIOT · 2010 to 2012
$6.3M
NHLBI NIH HHS U01 HL102225NIH HHS 1U01HL10222NIH HHS T32AI007306-33, AI078908, HL11113, HL117945, R37AI052353, R01AI136041, R01HL136209, R01AI130109, U19AO095219, K23AI118804
6 · The paper itself

Abstract

There is an acute need for advances in pharmacologic therapies and a better understanding of novel drug targets for severe asthma. Imatinib, a tyrosine kinase inhibitor, has been shown to improve forced expiratory volume in 1 s (FEV

Indexed as

asthma subtypesmitochondriapersonalized medicinepersonalized perturbation profilespharmacogeneticssystems biology

Identifiers

PMID33805900
PMCPMC8064376
OpenAlexW3137656131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.